BR0203656A - Uso de estatinas para inibir a formação de osteoclastos - Google Patents

Uso de estatinas para inibir a formação de osteoclastos

Info

Publication number
BR0203656A
BR0203656A BR0203656-8A BR0203656A BR0203656A BR 0203656 A BR0203656 A BR 0203656A BR 0203656 A BR0203656 A BR 0203656A BR 0203656 A BR0203656 A BR 0203656A
Authority
BR
Brazil
Prior art keywords
osteoclast formation
statin
statins
mammal
effective amount
Prior art date
Application number
BR0203656-8A
Other languages
English (en)
Inventor
Vijaykumar Mahalingappa Baragi
Rodhika Madhav Devalaraja
Brandon Robert Peters
Richard Raymond Renkiewicz
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0203656A publication Critical patent/BR0203656A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE ESTATINAS PARA INIBIR A FORMAçãO DE OSTEOCLASTOS". Método para inibir a formação de osteoclastos compreendendo a administração de uma quantidade terapeuticamente eficaz de uma estatina a um mamífero que disso necessite assim como composições farmacêuticas, kits para conter tais composições compreendendo uma estatina ou um método para tratar ou evitar um estado de doença selecionado do grupo constituído por: osteoporose, doença de Paget, osteólise, hipercalcemia maligna, osteogênese imperfecta, osteoartrite, perda óssea alveolar, efeitos secundários de terapia imunossupressiva e efeitos secundários do uso glucocorticóide crónica por inibição da formação de osteoclastos compreendendo a administração de uma quantidade terapeuticamente eficaz de uma estatina a um mamífero que disso necessite.
BR0203656-8A 2001-09-10 2002-09-09 Uso de estatinas para inibir a formação de osteoclastos BR0203656A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31845001P 2001-09-10 2001-09-10

Publications (1)

Publication Number Publication Date
BR0203656A true BR0203656A (pt) 2003-06-03

Family

ID=23238236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0203656-8A BR0203656A (pt) 2001-09-10 2002-09-09 Uso de estatinas para inibir a formação de osteoclastos

Country Status (13)

Country Link
US (1) US20030055101A1 (pt)
EP (1) EP1291017A3 (pt)
JP (1) JP2003104883A (pt)
KR (1) KR20030022725A (pt)
CN (1) CN1403081A (pt)
BR (1) BR0203656A (pt)
CA (1) CA2401319A1 (pt)
HU (1) HUP0202969A3 (pt)
IL (1) IL151571A0 (pt)
NZ (1) NZ521188A (pt)
PL (1) PL355958A1 (pt)
TW (1) TWI226238B (pt)
ZA (1) ZA200207233B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526730A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
EP1761270A1 (en) * 2004-06-23 2007-03-14 Merck & Co., Inc. Estrogen receptor modulators
KR101224256B1 (ko) * 2005-10-14 2013-01-18 한양대학교 산학협력단 레이저 기반의 이동 단말을 위한 다중채널의 장면구성 제어방법 및 장치
SG166829A1 (en) 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US20110086080A1 (en) * 2007-11-14 2011-04-14 Osteosphere, Llc Ex-vivo production of human demineralized bone matrix
US8506982B2 (en) * 2007-11-14 2013-08-13 Osteosphere, Llc Development of a human colloidal bone graft material
WO2009064917A2 (en) * 2007-11-14 2009-05-22 Osteosphere, Llc Generation of an hla-negative osteogenic precursor cell line
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2591782A1 (en) * 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof
TWI542569B (zh) * 2015-02-11 2016-07-21 高雄醫學大學 ３，５－二羥基戊酸的類似物用於成骨作用
CN109248338A (zh) * 2018-11-16 2019-01-22 张浩淼 可吸收膜及其制备方法和应用、牙种植体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
WO1999045923A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Methods of inhibiting bone resorption
US20010025028A1 (en) * 1998-03-13 2001-09-27 Merck & Co., Inc. Methods of inhibiting bone resorption
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
WO2001037876A2 (en) * 1999-11-24 2001-05-31 Bayer Aktiengesellschaft Methods of ameliorating abnormal bone states

Also Published As

Publication number Publication date
EP1291017A2 (en) 2003-03-12
KR20030022725A (ko) 2003-03-17
IL151571A0 (en) 2003-04-10
CN1403081A (zh) 2003-03-19
NZ521188A (en) 2004-06-25
US20030055101A1 (en) 2003-03-20
HU0202969D0 (pt) 2002-10-28
EP1291017A3 (en) 2003-07-02
ZA200207233B (en) 2004-03-09
JP2003104883A (ja) 2003-04-09
HUP0202969A3 (en) 2004-08-30
TWI226238B (en) 2005-01-11
HUP0202969A2 (hu) 2003-07-28
PL355958A1 (en) 2003-03-24
CA2401319A1 (en) 2003-03-10

Similar Documents

Publication Publication Date Title
BR0203656A (pt) Uso de estatinas para inibir a formação de osteoclastos
BR0211364A (pt) Composição farmacêutica para tratamento de doenças associadas com redução na massa óssea compreendendo o agonista ep4 como componente ativo
BR0115696A (pt) Uso de bisfosfonatos para tratamento de dor
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR9909597A (pt) Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
SE9901272D0 (sv) New improved formulation
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
EP1430061A4 (en) INCLUSION COMPOUND CONTAINING CUCURBITURIL DERIVATIVES AS RECEPTOR MOLECULE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
IS5890A (is) Aðferð til að gefa sýklalyf
BRPI0611814A2 (pt) moduladores parp e tratamento de cÂnceres
BR0016058A (pt) Compostos de fosfonato
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
GT199700009AA (es) Terapia combinada para la osteoporosis
ES2191475T3 (es) Conjugados de prostaglandina para el tratamiento o prevencion de enfermedades oseas.
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
BR0214614A (pt) Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2
BR0211203A (pt) Acilsemicarbazidas como inibidores de cinase dependente de ciclina úteis como agentes anti-câncer e anti-proliferativos
BR0008603A (pt) Método para tratamento de copd
DK1756046T3 (da) Arylalkylsulfonamider som terapeutiske midler til behandling af knoglelidelser
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
ATE208402T1 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1980 DE 16/12/2008.